OIPE IAP42 MAY 09 2006 PATENT & TRADEMARK OFFICE

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 6

Complete if Known	
Application Number	10/682,638
Filing Date	October 8, 2003
First Named Inventor	David L. SHELTON
Art Unit	1647
Examiner Name	J. Lockard
Attorney Docket Number	514712000500

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number: Number-Kind Code[2] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
JL	1.	US-2002/0072543-A1	06-13-2002	Olesen et al.	
	2.	US-2002/0146416-A1	10-10-2002	Presta et al.	
	3.	US-2003/0008807-A1	01-09-2003	Levine et al.	
	4.	US-2003/0072746-A1	04-17-2003	Miller	
	5.	US-2003/0203923-A1	10-30-2003	Ross et al.	
	6.	US-2004/0038874-A1	02-26-2004	Omoigui	
	7.	US-2004/0071701-A1	04-15-2004	Delafoy et al.	
	8.	US-2004/0097562-A1	05-20-2004	Olesen et al.	
	9.	US-2004/0121959-A1	06-24-2004	Boone et al.	
	10.	US-2005/0074821-A1	04-07-2005	Wild, Jr. et al.	
	11.	US-2005/0222035-A1	10-06-2005	Boone et al.	
	12.	US-2005/0265994-A1	12-01-2005	Shelton et al.	
	13.	US-RE 38,103-E	04-29-2003	Guay et al.	
	14.	US-5,656,435-A	08-12-1997	Nakahama et al.	
	15.	US-5,712,100-A	01-27-1998	Nakahama et al.	
	16.	US-6,022,875-A	02-08-2000	Zimmer et al.	
	17.	US-6,027,927-A	02-22-2000	Presta et al.	
	18.	US-6,399,780-B1	06-04-2002	Hudkins	
	19.	US-6,492,380-B1	12-10-2002	Ross et al.	
	20.	US-6,548,062-B2	04-15-2003	Buchkovich et al.	
	21.	US-6,548,640-B1	04-15-2003	Winter	
	22.	US-6,649,605-B2	11-18-2003	Olesen et al.	
JL	23.	US-6,919,426-B2	07-19-2005	Boone et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]-Number[4]-Kind Code[5] *(if known)*	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
JL	24.	EP-0 418 590-A1, B1	03-27-1991	Takeda Chemical Industries, Ltd.		
	25.	JP-63-295588-A	12-01-1988	Kyowa Hakko Kogyo KK	Translation of Abstract Only	
	26.	WO-90/10644-A1	09-20-1990	Lope Medicine AB		
	27.	WO-95/25795-A1	09-28-1995	Genentech, Inc.		
	28.	WO-98/19674-A2, A3	05-14-1998	Olesen et al.		
	29.	WO-01/52843-A1	07-26-2001	McGill University et al.		
	30.	WO-02/20513-A1	03-14-2002	Glaxo Group Limited		
	31.	WO-02/102232-A2, A3	12-27-2002	The Regents of the University of California		
	32.	WO-03/022261-A1	03-20-2003	Miller		
	33.	WO-2004/026329-A1	04-01-2004	Amgen, Inc.		
	34.	WO-2004/028448-A2, A3	04-08-2004	Miller		
	35.	WO-2004/032852-A2, A3	04-22-2004	Rinat Neuroscience Corp.		
	36.	WO-2005/019266-A2, A3	03-03-2005	Amgen, Inc.		
JL	37.	WO-2005/111077-A2, A3	11-24-2005	Rinat Neuroscience Corp. et al.		

Examiner Signature	/Jon Lockard/	Date Considered	07/16/2006

OIPE IAP42 MAY 09 2006 PATENT & TRADEMARK OFFICE

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/682,638
				Filing Date	October 8, 2003
				First Named Inventor	David L. SHELTON
				Art Unit	1647
(Use as many sheets as necessary)				Examiner Name	J. Lockard
Sheet	2	of	6	Attorney Docket Number	514712000500

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
JL	38.	Abbadie, C. et al. (June 24, 2003). "Impaired Neuropathic Pain Responses in Mice Lacking the Chemokine Receptor CCR2," *Proc. Natl. Acad. Sci. USA* 100(13):7947-7952.	
	39.	Aloe, L. et al. (1993). "The Synovium of Transgenic Arthritic Mice Expressing Human Tumor Necrosis Factor Contains a High Level of Nerve Growth Factor," *Growth Factors* 9(2):149-155.	
	40.	Aloe, L. et al. (Sept.-Oct. 1999). "Nerve Growth Factor in the Synovia of Patients with Rheumatoid Arthritis: Correlation with TNF-α and IL-1β and Possible Functional Significance," *Clin. Exp. Rheumatol.* 17(5):632-633.	
	41.	Altschul, S.F. et al. (1997). "Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs," *Nucleic Acids Res.* 25(17):3389-3402.	
	42.	American Chemical Society (1987-1991). Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34237CS, column 3, lines 5-7.	
	43.	American Chemical Society (1987-1991). Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34237CS, column 3, lines 55-60.	
	44.	American Chemical Society (1987-1991). Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34237CS, column 3, lines 66-69.	
	45.	American Chemical Society (1987-1991). Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34238CS, column 1, lines 41-44.	
	46.	American Chemical Society (1987-1991). Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34238CS, column 2, lines 25-27.	
	47.	American Chemical Society (1987-1991). Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34238CS, column 2, lines 32-33.	
	48.	American Chemical Society (1987-1991). Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34239CS, column 3, lines 48-50.	
	49.	American Chemical Society (1987-1991). Chemical Abstracts, 12th Collective Index, Chemical Substances, Volumes 106-115, page 34239CS, column 3, lines 52-53.	
	50.	Barbas III, C.F. et al. (April 1994). "*In vitro* Evolution of a Neutralizing Human Antibody to Human Immunodeficiency Virus Type 1 to Enhance Affinity and Broaden Strain Cross-Reactivity," *Proc. Natl. Acad. Sci. USA* 91:3809-3813.	
	51.	Barbas III, C.F. et al. (2001). "Vector pComb3X, Figure 2.2" *In* "Phage-Display Vectors" Chapter 2 *In* Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, pp. 2.9-2.13.	
	52.	Bellamy, N. (May 1989). "Pain Assessment in Osteoarthritis: Experience With the WOMAC Osteoarthritis Index," *Semin. Arthritis Rheum.* 18(4 Suppl. 2):14-17.	
	53.	Bellamy, N. et al. (December 1988). "Validation Study of WOMAC: A Health Status Instrument for Measuring Clinically Important Patient Relevant Outcomes to Antirheumatic Drug Therapy in Patients with Osteoarthritis of the Hip or Knee," *J. Rheumatol.* 15(12):1833-1840.	
	54.	Bibel, M. et al. (December 1, 2000). "Neurotrophins: Key Regulators of Cell Fate and Cell Shape in the Vertebrate Nervous System," *Genes Dev.* 14(23):2919-2937.	
JL	55.	Brosseau, L. et al. (2003). "Thermotherapy for Treatment of Osteoarthritis," *The Cochrane Database of Systematic Reviews* Issue 4, Art No. CD004522, pp. 1-20.	

Examiner Signature	/Jon Lockard/	Date Considered	07/16/2006

OIPE
MAY 09 2006
PATENT & TRADEMARK OFFICE
IAP42

ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 6

Complete if Known	
Application Number	10/682,638
Filing Date	October 8, 2003
First Named Inventor	David L. SHELTON
Art Unit	1647
Examiner Name	J. Lockard
Attorney Docket Number	514712000500

JL	56.	Chaplan, S.R. et al. (1994). "Quantitative Assessment of Tactile Allodynia in the Rat Paw," *J. Neuroscience Methods* 53:55-63.	
	57.	Chen, Y. et al. (November 5, 1999). "Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-Matured Fab in Complex with Antigen," *J. Mol. Biol.* 293(4):865-881.	
	58.	Choi, S-S. et al. (2003). "Antinociceptive Mechanisms of Orally Administered Decursinol in the Mouse," *Life Sciences* 73(4):471-485.	
	59.	Clohisy, D.R. et al. (2003). "Skeletal Complications of Malignancy: Bone Cancer Pain," *Clinical Orthopaedics and Related Research* 415S:S279-S288.	
	60.	Corey, E. et al. (June 1, 2002). "Establishment and Characterization of Osseous Prostate Cancer Models: Intra-Tibial Injection of Human Prostate Cancer Cells," *Prostate* 52(1):20-33.	
	61.	Dicou, E. et al. (1996). "Nerve Growth Factor (NGF) Autoantibodies and NGF in the Synovial Fluid: Implications in Spondylarthropathies," *Autoimmunity* 24(1):1-9.	
	62.	Dicou, E. et al. (December 13, 1993). "Increased Frequency of NGF in sera of Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients," *NeuroReport* 5(3):321-324.	
	63.	Dicou, E. et al. (January 1994). "Natural Autoantibodies Against the Nerve Growth Factor in Autoimmune Diseases," *J. Neuroimmunol.* 49(1):224 (Erratum).	
	64.	Dicou, E. et al. (May 1997). "Evidence That Natural Autoantibodies Against the Nerve Growth Factor (NGF) May Be Potential Carriers of NGF," *J. Neuroimmunol.* 75:200-203.	
	65.	Dicou, E. et al. (September 1993). "Natural Autoantibodies Against the Nerve Growth Factor in Autoimmune Diseases," *J. Neuroimmunol.* 47(2):159-167.	
	66.	Edoff, K. et al. (February 2000). "Retrograde Tracing and Neuropeptide Immunohistochemistry of Sensory Neurones Projecting to the Cartilaginous Distal Femoral Epiphysis of Young Rats," *Cell & Tissue Research* 299(2):193-200.	
	67.	Fawcett, D.W. (1986). "Bone" Chapter 8 *In* A Textbook of Histology, Dreibelbis, D. ed., Eleventh Edition, W.B. Saunders Co.: Philadelphia, PA, pp. 211-216 and Table of Contents pp. v-xi.	
	68.	Fischer, H.P. et al. (June 1998). "A Possible Role for Saliva as a Diagnostic Fluid in Patients with Chronic Pain," *Semin. Arthritis Rheum.* 27(6):348-359.	
	69.	Fjell, J. et al. (February 1999). "In Vivo NGF Deprivation Reduces SNS Expression and TTX-R Sodium Currents in IB4-Negative DRG Neurons," *J. Neurophysiol.* 81(2):803-810.	
	70.	García-Castellano, J.M. et al. (2000). "Is Bone a Target-Tissue for the Nervous System? New Advances on the Understanding of Their Interactions," *Iowa Orthop. J.* 20:49-58.	
	71.	Garrett, N.E. et al. (July 11, 1997). "Effect of Capsaicin on Substance P and Nerve Growth Factor in Adjuvant Arthritic Rats," *Neurosci. Lett.* 230:5-8.	
	72.	Gavilondo, J.V. et al. (July 2000). "Antibody Engineering at the Millennium," *BioTechniques* 29:128-145.	
	73.	GenBank Accession No. CAA09181, created December 2, 1998, ~~located at <http://www.ncbi.nlm.nih.gov> last visited October 10, 2006, two pages.~~ Patterson et al.	
	74.	GenBank Accession No. P01859, created July 21, 1986, ~~located at <http://www.ncbi.nlm.nih.gov> last visited October 10, 2006, four pages.~~ Ellison et al.	
	75.	Greene, L.A. et al. (July 1976). "Establishment of a Noradrenergic Clonal Line of Rat Adrenal Pheochromocytoma Cells Which Respond to Nerve Growth Factor," *Proc. Nat. Acad. Sci. USA* 73(7):2424-2428.	
	76.	Halliday, D.A. et al. (June 1998). "Elevated Nerve Growth Factor Levels in the Synovial Fluid of Patients With Inflammatory Joint Disease," *Neurochem. Res.* 23(6):919-922.	
	77.	Hasselström, J. et al. (July 1996). "Disposition and Analgesic Effects of Systemic Morphine, Morphine-6-glucuronide and Normorphine in Rat," *Pharmacology & Toxicology* 79(1):40-46.	
	78.	Haynes, M.K. et al. (December 2002). "Phenotypic Characterization of Inflammatory Cells From Osteoarthritic Synovium and Synovial Fluids," *Clin. Immunol.* 105(3):315-325.	
JL	79.	Hill, R. (July 2000). "NK_1 (Substance P) Receptor Antagonists - Why Are They Not Analgesic in Humans?" *Trends Pharmacol. Sci.* 21(7):244-246.	

Examiner Signature	/Jon Lockard/	Date Considered	07/16/2006

pa- 1062734

MAY 09 2006
PATENT & TRADEMARK OFFICE
IAP42

ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	4	of	6

Complete if Known	
Application Number	10/682,638
Filing Date	October 8, 2003
First Named Inventor	David L. SHELTON
Art Unit	1647
Examiner Name	J. Lockard
Attorney Docket Number	514712000500

JL	80.	Honoré, P. et al. (2000). "Cellular and Neurochemical Remodeling of the Spinal Cord in Bone Cancer Pain," *Prog. Brain Res.* 129:389-397.	
	81.	Honoré, P. et al. (May 2000). "Osteoprotegerin Blocks Bone Cancer-Induced Skeletal Destruction, Skeletal Pain and Pain-Related Neurochemical Reorganization of the Spinal Cord," *Nat. Med.* 6(5):521-528.	
	82.	Honoré, P. et al. (June 23, 2000). "Murine Models of Inflammatory, Neuropathic and Cancer Pain Each Generates a Unique Set of Neurochemical Changes in the Spinal Cord and Sensory Neurons," *Neuroscience* 98(3):585-598.	
	83.	Huang, E.J. et al. (2001). "Neurotrophins: Roles in Neuronal Development and Function," *Annu. Rev. Neurosci.* 24:677-736.	
	84.	Hunt, S.P. et al. (August 13, 1987). "Induction of c-*fos*-like Protein in Spinal Cord Neurons Following Sensory Stimulation," *Nature* 328:632-634.	
	85.	Huse, W.D. et al. (1993). "Increased Antibody Affinity and Specificity by Codon-Based Mutagenesis," *Intern. Rev. Immunol.* 10:129-137.	
	86.	Iadarola, M.J. et al. (1988). "Differential Activation of Spinal Cord Dynorphin and Enkephalin Neurons During Hyperalgesia: Evidence Using cDNA Hybridization," *Brain Res.* 455(2):205-212.	
	87.	International Search Report for PCT Application No. PCT/US03/32113, filed October 8, 2003, mailed April 10, 2006, four pages.	
	88.	International Search Report for PCT Application No. PCT/US04/05162 filed February 19, 2004, mailed March 28, 2006, four pages.	
	89.	International Search Report for PCT Application No. PCT/US2005/011786, filed July 4, 2005, mailed February 20, 2006, five pages.	
	90.	Jongen, J.L.M. et al. (2002). "Neurotrophic Factors and Cancer Pain: The Expression of NGF, GDNF and BDNF by the Murine Osteolytic Sarcoma Cell Line 2472 in vitro and in vivo and Their Potential Involvement in Bone Cancer Pain," *32nd Annual Meeting of the Society for Neuroscience,* Orlando, FL, (November 2-7, 2002), Abstract 52.2, located at <http://sfn.scholarone.com/iten2002/main.html>, last visited March 2, 2006, two pages.	
	91.	Kasai, M. et al. (1999). "Endogenous Nerve Growth Factor Increases the Sensitivity to Bradykinin in Small Dorsal Root Ganglion Neurons of Adjuvant Inflamed Rats," *Neuroscience Letters* 272(1):41-44.	
	92.	Kazemier, B. et al. (1996). "Determination of Active Single Chain Antibody Concentrations in Crude Periplasmic Fractions," *J. Immunol. Methods* 194(2):201-209.	
	93.	Lewin, G.R. et al. (May 1993). "Nerve Growth Factor-Induced Hyperalgesia in the Neonatal and Adult Rat," *J. Neurosci.* 13(5):2136-2148.	
	94.	Luger, N.M. et al. (May 15, 2001). "Osteoprotegerin Diminishes Advanced Bone Cancer Pain," *Cancer Res.* 61:4038-4047.	
	95.	Luger, N.M. et al. (2002). "Efficacy of Systemic Morphine Suggests a Fundamental Difference in the Mechanisms that Generate Bone Cancer vs. Inflammatory Pain," *Pain* 99:397-406.	
	96.	Mach, D.B. et al. (2002). "Origins of Skeletal Pain: Sensory and Sympathetic Innervation of the Mouse Femur," *Neuroscience* 113(1):155-166.	
	97.	Mantyh, P.W. et al. (March 2002). "Molecular Mechanisms of Cancer Pain," *Nature Reviews Cancer* 2(3):201-209.	
	98.	McCarthy, B.G. et al. (October 1995). "Cutaneous Innervation in Sensory Neuropathies," *Neurology* 45:1848-1855.	
↓	99.	McDonald, N.Q. et al. (December 5, 1991). "New Protein Fold Revealed by a 2.3-Å Resolution Crystal Structure of Nerve Growth Factor," *Nature* 354:411.	
JL	100.	McMahon, S.B. (March 29, 1996). "NGF as a Mediator of Inflammatory Pain," *Phil. Trans. R. Soc. Land. B* 351(1338):431-440.	

Examiner Signature	/Jon Lockard/	Date Considered	07/16/2006

pa-1062734

OIPE
MAY 0 9 2006
PATENT & TRADEMARK OFFICE
IAP42

ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 6

Complete if Known	
Application Number	10/682,638
Filing Date	October 8, 2003
First Named Inventor	David L. SHELTON
Art Unit	1647
Examiner Name	J. Lockard
Attorney Docket Number	514712000500

JL	101.	Molander, C. et al. (1987). "Spinal Cord Projections From Hindlimb Muscle Nerves in the Rat Studied by Transganglionic Transport of Horseradish Peroxidase, Wheat Germ Agglutinin Conjugated Horseradish Peroxidase, or Horseradish Peroxidase With Dimethylsulfoxide," *J. Comp. Neurol.* 260:246-255.	
	102.	Muller, Y.A. et al. (1998). "VEGF and the Fab Fragment of a Humanized Neutralizing Antibody: Crystal Structure of the Complex at 2.4 Å Resolution and Mutational Analysis of the Interface," *Structure* 6(9):1153-1167.	
	103.	Myers, R.R. et al. (September 1996). "Reduced Hyperalgesia in Nerve-Injured WLD Mice: Relationship to Nerve Fiber Phagocytosis, Axonal Degeneration, and Regeneration in Normal Mice," *Exp. Neurol.* 141(1):94-101.	
	104.	Niissalo, S. et al. (June 2002). "Neuropeptides in Experimental and Degenerative Arthritis," *Ann. N.Y. Acad. Sci.* 966:384-399.	
	105.	Noguchi, K. et al. (1991). "Dynorphin Expression and Fos-like Immunoreactivity Following Inflammation Induced Hyperalgesia are Colocalized in Spinal Cord Neurons," *Molecular Brain Research* 10(3):227-233.	
	106.	Peter, E.A. et al. (October 30, 2001). "Ibuprofen Versus Acetaminophen with Codeine for the Relief of Perineal Pain after Childbirth: A Randomized Controlled Trial," *CMAJ* 165(9):1203-1209.	
	107.	Pezet, S. et al. (February 1, 2001). "Differential Regulation of NGF Receptors in Primary Sensory Neurons by Adjuvant-Induced Arthritis in the Rat," *Pain* 90(1-2):113-125.	
	108.	Pozza, M. et al. (May 2000). "A Histochemical Study of the Rheumatoid Synovium: Focus on Nitric Oxide, Nerve Growth Factor High Affinity Receptor, and Innervation," *J. Rheumatol.* 27(5):1121-1127.	
	109.	Puigdellívol-Sánchez, A. et al. (1998). "Sciatic and Femoral Nerve Sensory Neurones Occupy Different Regions of the L4 Dorsal Root Ganglion in the Adult Rat," *Neurosci. Lett.* 251(3):169-172.	
	110.	Puigdellívol-Sánchez, A. et al. (October 1, 2000). "Contribution of Femoral and Proximal Sciatic Nerve Branches to the Sensory Innervation of Hindlimb Digits in the Rat," *The Anatomical Record* 260(2):180-188.	
	111.	Rader, C. et al. (2001). "Antibody Engineering" Chapter 13 *In* Phage Display, A Laboratory Manual, Barbas III, C.F. et al. eds., Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, pp. 13.1-13.15.	
	112.	Rosok, M.J. et al. (September 13, 1996). "A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab," *The Journal of Biological Chemistry* 271(37):22611-22618.	
	113.	Rudikoff, S. et al. (March 1982). "Single Amino Acid Substitution Altering Antigen-Binding Specificity," *Proc. Natl. Acad. Sci. USA* 79:1979-1983.	
	114.	Sabino, M.A.C. et al. (December 15, 2002). "Simultaneous Reduction in Cancer Pain, Bone Destruction, and Tumor Growth by Selective Inhibition of Cyclooxygenase-2," *Cancer Res.* 62:7343-7349.	
	115.	Sabino, M.A.C. et al. (May 1, 2003). "Different Tumors in Bone Each Give Rise to a Distinct Pattern of Skeletal Destruction, Bone Cancer-Related Pain Behaviors and Neurochemical Changes in the Central Nervous System," *International Journal of Cancer* 104(5):550-558.	
	116.	Safieh-Garabedian, B. et al. (August 1995). "Contribution of Interleukin-1β to the Inflammation-Induced Increase in Nerve Growth Factor Levels and Inflammatory Hyperalgesia," *Br. J. Pharmacol.* 115(7):1265-1275.	
	117.	Schwei, M.J. et al. (December 15, 1999). "Neurochemical and Cellular Reorganization of the Spinal Cord in a Murine Model of Bone Cancer Pain," *J. Neuroscience* 19(24):10886-10897.	
JL	118.	Shelton, D.L. et al. (December 1984). "Expression of the β-nerve Growth Factor Gene Correlates with the Density of Sympathetic Innervation in Effector Organs," *Proc. Natl. Acad. Sci. USA* 81:7951-7955.	

Examiner Signature	/Jon Lockard/	Date Considered	07/16/2006

pa- 1062734

OIPE
MAY 08 2006
PATENT & TRADEMARK OFFICE
IAP42

ALTERNATIVE TO PTO/SB/08a/b (07-05)

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 6 of 6

Complete if Known	
Application Number	10/682,638
Filing Date	October 8, 2003
First Named Inventor	David L. SHELTON
Art Unit	1647
Examiner Name	J. Lockard
Attorney Docket Number	514712000500

JL	119.	Shelton, D.L. et al. (1995). "Neurotrophins and Neurotrophin Antagonists as Potential Therapeutics," *Restorative Neurology and Neuroscience* 8(1-2):99-100.	
	120.	Shu, X. et al. (1999). "Nerve Growth Factor Acutely Sensitizes the Response of Adult Rat Sensory Neurons to Capsaicin," *Neurosci. Lett.* 274(3):159-162.	
	121.	Stedman, T.L. (1982). Illustrated Stedman's Medical Dictionary, Williams & Wilkins: Baltimore, MD, 24th Edition, pg. 670.	
	122.	Szekanecz, Z. et al. (June 2000). "Temporal Expression of Inflammatory Cytokines and Chemokines in Rat Adjuvant-Induced Arthritis," *Arthritis & Rheumatism* 43(6):1266-1277.	
	123.	Tang, Y. et al. (September 24, 1999). "Use of a Peptide Mimotope to Guide the Humanization of MRK-16, an Anti-P-Glycoprotein Monoclonal Antibody," *The Journal of Biological Chemistry* 274(39):27371-27378.	
	124.	Thompson, J.E. et al. (1999). "A Fully Human Antibody Neutralising Biologically Active Human TGFβ2 for use in Therapy," *J. Immunol. Methods* 227:17-29.	
	125.	Tofaris, G.K. et al. (August 1, 2002). "Denervated Schwann Cells Attract Macrophages by Secretion of Leukemia Inhibitory Factor (LIF) and Monocyte Chemoattractant Protein-1 in a Process Regulated by Interleukin-6 and LIF," *J. Neurosci.* 22(15):6696-6703.	
	126.	Tsujino, H. et al. (February 2000). "Activating Transcription Factor 3 (ATF3) Induction by Axotomy in Sensory and Motoneurons: A Novel Neuronal Marker of Nerve Injury," *Molecular & Cellular Neuroscience* 15(2):170-182.	
	127.	Vajdos, F.F. et al. (2002), "Comprehensive Functional Maps of the Antigen-Binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis," *J. Mol. Biol.* 320:415-428.	
	128.	Vanderah, T.W. et al. (April 2001). "Mechanisms of Opioid-Induced Pain and Antinociceptive Tolerance: Descending Facilitation and Spinal Dynorphin," *Pain* 92(3):5-9.	
	129.	Vigneti, E. et al. (1993). "Production and Characterization of a Monoclonal Antibody Against Nerve Growth Factor (NGF) Which Recognizes Rodent and Human NGF," *Year Immunol.* 7:146-149.	
	130.	Villanueva, L. (December 2000). "Is There a Gap Between Preclinical and Clinical Studies of Analgesia?" *Trends Pharmacol. Sci.* 21(12):461-462.	
	131.	Wiesmann, C. et al. (September 9, 1999). "Crystal Structure of Nerve Growth Factor in Complex with the Ligand-Binding Domain of the TrkA Receptor," *Nature* 401(6749):184-188.	
	132.	Winter, C.A. et al. (June 1966). "Treatment of Adjuvant Arthritis in Rats with Anti-inflammatory Drugs," *Arthritis Rheum.* 9(3):394-404.	
	133.	Woolf, C.J. et al. (1994). "Nerve Growth Factor Contributes to the Generation of Inflammatory Sensory Hypersensitivity," *Neuroscience* 62(2):327-331.	
	134.	Wu, H. et al. (November 19, 1999). "Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues," *J. Mol. Biol.* 294(1):151-162.	
	135.	Wu, S.M. et al. (1998). "Oxidized α_2-Macroglobulin (α_2M) Differentially Regulates Receptor Binding by Cytokines/Growth Factors: Implications for Tissue Injury and Repair Mechanisms in Inflammation," *The Journal of Immunology* 161:4356-4365.	
	136.	Wu, Z. et al. (December 2000). "Immunohistochemical Study of NGF and its Receptors in the Synovial Membrane of the Ankle Joint of Adjuvant-Induced Arthritic Rats," *Histochem. Cell Biol.* 114(6):453-459.	
JL	137.	Yelton, D.E. et al. (1995). "Affinity Maturation of the BR96 Anti-Carcinoma Antibody by Codon-Based Mutagenesis," *The Journal of Immunology* 155:1994-2004.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1]Applicant's unique citation designation number (optional). [2]Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Jon Lockard/	Date Considered	07/16/2006